Patents by Inventor Yoshiharu Hiruma
Yoshiharu Hiruma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10723800Abstract: To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.Type: GrantFiled: May 25, 2012Date of Patent: July 28, 2020Assignee: Daiichi Sankyo Company, LimitedInventors: Yoshiharu Hiruma, Eisuke Tsuda
-
Patent number: 10308715Abstract: To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.Type: GrantFiled: October 11, 2017Date of Patent: June 4, 2019Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Yoshiharu Hiruma, Eisuke Tsuda
-
Patent number: 9815899Abstract: To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.Type: GrantFiled: August 14, 2015Date of Patent: November 14, 2017Assignee: Daiichi Sankyo Company, LimitedInventors: Yoshiharu Hiruma, Eisuke Tsuda
-
Patent number: 9751944Abstract: Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.Type: GrantFiled: June 5, 2015Date of Patent: September 5, 2017Assignee: Daiichi Sankyo Company, LimitedInventors: Yoshiharu Hiruma, Eisuke Tsuda, Takeshi Takizawa, Makiko Nakayama
-
Patent number: 9464133Abstract: Provided is a pharmaceutical composition for the treatment and/or prophylaxis of abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.Type: GrantFiled: March 29, 2013Date of Patent: October 11, 2016Assignee: Daiichi Sankyo Company, LimitedInventors: Yoshiharu Hiruma, Takako Kimura, Hironari Shimizu
-
Publication number: 20150344578Abstract: To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.Type: ApplicationFiled: August 14, 2015Publication date: December 3, 2015Applicant: Daiichi Sankyo Company, LimitedInventors: Yoshiharu Hiruma, Eisuke Tsuda
-
Publication number: 20150299318Abstract: Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.Type: ApplicationFiled: June 5, 2015Publication date: October 22, 2015Applicant: Daiichi Sankyo Company, LimitedInventors: Yoshiharu Hiruma, Eisuke Tsuda, Takeshi Takizawa, Makiko Nakayama
-
Patent number: 9114131Abstract: An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109.Type: GrantFiled: October 4, 2011Date of Patent: August 25, 2015Assignee: Daiichi Sankyo Company, LimitedInventors: Ichiro Watanabe, Yoshiharu Hiruma, Eisuke Tsuda, Tatsuji Matsuoka, Toshiaki Ohtsuka, Tohru Takahashi, Toshinori Agatsuma, Sandra Miller, Robert Mühlbacher, Kathrin-Ladetzki Baehs, Steffen Runz, Ulrike Schubert, Ingrid Schuster, Dirk Ponsel
-
Patent number: 9090692Abstract: To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.Type: GrantFiled: April 27, 2012Date of Patent: July 28, 2015Assignee: Daiichi Sankyo Company, LimitedInventors: Yoshiharu Hiruma, Eisuke Tsuda
-
Patent number: 9079959Abstract: Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.Type: GrantFiled: September 30, 2013Date of Patent: July 14, 2015Assignee: Daiichi Sankyo Company, LimitedInventors: Yoshiharu Hiruma, Eisuke Tsuda, Takeshi Takizawa, Makiko Nakayama
-
Publication number: 20150125470Abstract: Provided is a pharmaceutical composition for the treatment and/or prophylaxis of abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.Type: ApplicationFiled: March 29, 2013Publication date: May 7, 2015Applicant: Daiichi Sankyo Company, LimitedInventors: Yoshiharu Hiruma, Jun Hasegawa
-
Patent number: 8980272Abstract: The present invention relates to a method of detecting metabolic bone disorders using a gene expressed at a high level in osteoclasts, a method of screening for a compound effective for treatment and/or prevention of metabolic bone disorders, and a pharmaceutical composition for treatment and/or prevention of metabolic bone disorders. Specifically, the present invention relates to a method of detecting metabolic bone disorders using expression of the human DC-STAMP gene as an indicator, a pharmaceutical composition containing an antibody which is capable of specifically recognizing human DC-STAMP and suppressing formation of osteoclasts, and so forth.Type: GrantFiled: August 11, 2006Date of Patent: March 17, 2015Assignee: Sankyo Company, LimitedInventors: Hisayuki Nomiyama, Toshio Kukita, Yoshiharu Hiruma
-
Publication number: 20150056189Abstract: Provided is a pharmaceutical composition for the treatment and/or prophylaxis of abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.Type: ApplicationFiled: March 29, 2013Publication date: February 26, 2015Applicant: Daiichi Sankyo Company, LimitedInventors: Yoshiharu Hiruma, Takako Kimura, Hironari Shimizu
-
Publication number: 20140065146Abstract: Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.Type: ApplicationFiled: September 30, 2013Publication date: March 6, 2014Applicant: Daiichi Sankyo Company, LimitedInventors: Yoshiharu Hiruma, Eisuke Tsuda, Takeshi Takizawa, Makiko Nakayama
-
Patent number: 8575316Abstract: Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.Type: GrantFiled: April 7, 2010Date of Patent: November 5, 2013Assignee: Daiichi Sankyo Company, LimitedInventors: Yoshiharu Hiruma, Eisuke Tsuda, Takeshi Takizawa, Makiko Nakayama
-
Publication number: 20130280276Abstract: An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109.Type: ApplicationFiled: October 4, 2011Publication date: October 24, 2013Inventors: Ichiro Watanabe, Yoshiharu Hiruma, Eisuke Tsuda, Tatsuji Matsuoka, Toshiaki Ohtsuka, Tohru Takahashi, Toshinori Agatsuma, Sandra Miller, Robert Mühlbacher, Kathrin-Ladetzki Baehs, Steffen Runz, Ulrike Schubert, Ingrid Schuster, Dirk Ponsel
-
Patent number: 8546540Abstract: To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.Type: GrantFiled: October 8, 2008Date of Patent: October 1, 2013Assignee: Daiichi Sankyo Company, LimitedInventors: Yoshiharu Hiruma, Eisuke Tsuda
-
Publication number: 20120251485Abstract: To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.Type: ApplicationFiled: April 27, 2012Publication date: October 4, 2012Inventors: Yoshiharu Hiruma, Eisuke Tsuda
-
Publication number: 20120230988Abstract: To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.Type: ApplicationFiled: May 25, 2012Publication date: September 13, 2012Inventors: Yoshiharu Hiruma, Eisuke Tsuda
-
Patent number: 8183272Abstract: Compounds exhibiting calcium receptor antagonist activity that are safe and orally administrable having Formula (I) or pharmaceutically acceptable salts thereof:Type: GrantFiled: June 23, 2011Date of Patent: May 22, 2012Assignee: Daiichi Sankyo Company, LimitedInventors: Akira Nakao, Kentoku Gotanda, Kazumasa Aoki, Shimpei Hirano, Yoshiharu Hiruma, Takeshi Shiiki